Would acetazolamide inhibit progression of atheromatous vascular calcification?

Malcolm Cochran

Gilberton, South Australia 5081, Australia

ABSTRACT

Vascular calcification is a recognised source of morbidity among mid-age and elderly subjects. Its development follows classical mineralisation pathways, inhibited by acidosis. It is known that the final mechanism of tissue mineralization involves three processes, all of which are highly pH dependent. Calcium interacts with phosphate in its trivalent form, but this step is inhibited by pyrophosphate, itself a source of phosphate when hydrolysed by alkaline phosphatase. Separately, matrix vesicles create nucleation sites and may indirectly disrupt vascular smooth muscle cells. Metabolic acidosis acts at every point to delay mineralization. The diuretic acetazolamide creates a sustained mild acidosis with some phosphate loss and, though usually ineffective in the experimental model, has been used with success in certain clinical conditions. We suggest that acetazolamide, well studied and tolerated, might inhibit progression of vascular calcification in subjects at risk through its dual action of lowering tissue pH and local phosphate concentration.

Introduction

The many aspects of vascular calcification have been the subject of a great deal of investigative work over the last two decades. The subintimal and medial forms both involve the layer of smooth muscle cells (VSMC), with the former following atheromatous inflammatory damage, and the latter, Monckeberg's sclerosis, occurring with age. The arterial wall consists of the thin endothelial layer, lying on the elastic tunica intima, supported by the tunica media, mainly VSMC. The latter provide strength and responsiveness but they also secrete the collagen and elastin fibres and proteoglycans which contribute to the vessel's structure. These cells are analogous to fibroblasts, osteoblasts or chondrocytes at their respective sites [1]. When atheroma disrupts the sub-intimal layer of VSMC, the foreign material, especially LDL, attracts macrophages, particularly those with an inflammatory response [2,3]. Simply with age, more deeply in the media, the differentiation of VSMC into fibroblasts leads to stiffening of the wall [4]. In either case, the process is not benign with the inelasticity and irregular lumen increasing shear stress and turbulence in the blood flow [5,6]. The association between vascular calcification in the coronary arteries and plaque stabilisation or destabilisation is unclear [7,8] though it generally agreed that there is increased risk of thrombosis. However, at a given site, there is no clear link between the two [9].

The prevalence of the condition among adults is remarkably high. Based on samples of femoral-popliteal arteries from a large number of transplant donors, about 50% of cases showed calcification [10] and similar results were found in a study using non-invasive techniques [11] where it was a common finding (c.70%) among elderly subjects but was also evident in some young adults. Obesity was a significant risk factor, dominating the effect of tobacco [10].

It is abundantly evident that the calcification, when it occurs, is a complex process mimicking many aspects of normal bone formation [12,13]; however, that in itself suggests targets to inhibit progression.

A surprising finding has been the observation that Statin use is apparently associated with increased vascular calcification as shown by imaging [14,15]. It is unclear if this is a direct effect or simply follows inactivation and scarring down of atheromatous plaques.

Discussion

The discussion and suggestion that follows refer to the mineralisation process in subjects with a normal or near normal metabolic state, in particular excluding the case of renal failure which is, however, the usual model in non-clinical studies. Nor have we considered the upstream subtleties of bone formation modulated by, for example, FGF23 and alpha-KLOTHO, Vit D metabolite receptors, osteoclast control factors (RANK and RANK Ligand), Osteoprotegerin or Sclerostin and possibly other glycoproteins. We confine the argument to actual mineralisation in its final stages, these being sensitive to pH change.

Mechanisms of vascular calcification

In normal bone mineralisation and vascular calcification, the final product is hydroxy-apatite but this stable salt is the end product of a series of transformations starting with octocalcium phosphate [16,17]. The two determinants of octocalcium phosphate formation in an aqueous medium are the concentrations of calcium and trivalent phosphate ions. The phosphate species in the ECF are made up of mono-, di-, and trivalent phosphate, and it is the strongly negative trivalent phosphate ion that interacts with the positively charged divalent calcium. Of the total plasma phosphate concentration, only a small fraction exists as trivalent phosphate and this is significantly pH sensitive. Even in mild acidosis, eg pH 7.3, there is ultimately about a 20% decrease in the prevailing concentration of trivalent phosphate and so the rate of complexation with calcium is correspondingly slower.

This effect of pH shift on trivalent phosphate is only one of three closely matching mechanisms which explain the mineralisation failure of acidosis. The product of cellular reactions involving high energy phosphate bonds is pyrophosphate (POP). The classic source of POP is deactivation of ATP but most molecules in a chain of reactions require a high energy phosphate bond. This molecule is a strong inhibitor of mineralisation [18] and its breakdown product, the phosphate ion, means that it has a dual role in any shift between promotion or prevention of mineralisation. More POP means less local phosphate. The enzyme which degrades POP is alkaline phosphatase [19], so acidosis would mean the concentration of POP would be relatively higher [20], tending to slow mineralisation. Accordingly, a fall in plasma pH inhibits calcification directly, through reduction of local phosphate concentration, sourced from POP, and further reduction of the trivalent moiety; and indirectly by reducing hydrolysis of inhibitory POP.

Although the inhibitory action of Statins blocks a series of downstream reactions, which would otherwise release POP molecules, these are confined to the hepatocyte, so cannot be considered relevant to this discussion.

Matrix vesicles were described many years ago, first in calcifying cartilage [21] then in mouse calvaria [22]. They bud off as portions of the cell membrane, carrying alkaline phosphatase, and actively accumulate calcium to begin the process of mineralisation in the intercellular space, making it independent of cellular activity. They have a definite role in vascular calcification [23,24]. Their uptake of calcium is strongly reduced with lower pH thus introducing a further point for inhibition [25,26].

The VSMC may pick up some of the mineral particles by pinocytosis, disrupting their structure [8,26,27]. On the other hand, there is a clear picture of VSMC differentiating into fibroblast or osteoblast cell types, with the appearance of all the known signalling molecules for mineralisation and its production as discussed here. This would match the effect seen with ageing. Ultrastructural studies suggest that inside the cell, long crystalline hydroxy-apatite structures appear within an amorphous sheath, along with known trophic factors for bone formation [26].

Calcification may additionally be promoted by induction of mineralisation pathways in the presence of an elevated plasma phosphate but this probably does not apply in normophosphataemia [28,29,30]: it would require a substantial degree of renal failure.

There are then two forms of calcification at work: one, somewhat haphazard and destructive to the cell architecture; the other a cellular change with the features of organised mineralisation [6,26].

A role for induced acidosis

Given the requirement for a physiologic pH for mineralisation to proceed, and the evidence for inhibition by metabolic acidosis, we can consider the possibility of offsetting the final stage of vascular calcification by inducing a mild acidosis.

This is easily achieved with the diuretic acetazolamide, a carbonic anhydrase inhibitor, the target enzyme being found particularly in the kidney, brain, and stomach. It was initially of minor use, but was found to have some anti-epileptic properties and also to reduce sleep apnoea at high altitude [31]. Many other studies have shown that it increases cerebral blood flow, though it is unclear how that affects the neurone [32]. It is well tolerated and with usual dosing has no significant side-effects [33].

As a renal carbonic anhydrase inhibitor, it prevents hydrolysis of bicarbonate in the proximal tubule, increasing the negative luminal potential, so reducing sodium reabsorption and associated movement of water. The loss of bicarbonate from plasma shifts the equilibrium towards a sustained acidosis with a fall in plasma bicarbonate of about 4 mmol/L [33] corresponding to a change in blood pH from ~7.4 to ~7.3 for about 12 h. Phosphate, reabsorbed proximally by Na-P co-transporters, also pH sensitive [34,35], is washed downstream with a minor decrease in plasma level.

Acetazolamide therefore creates a reduction both in pH and plasma phosphate. Both effects, but the pH fall especially, would be central in inhibiting mineralisation. There are reports of its successful use even in the hyperphosphataemic state, eg, tumorous calcinosis [36,37,38]. A comprehensive review of the pathophysiology of vascular calcification using laboratory models generally with induced severe renal impairment, supported the idea of prevention by acidosis, but understandably found acetazolamide rather ineffective in this setting [39,40].

Hypothesis

Acting at the kidney level, there would obviously be no response to acetazolamide among patients with chronic renal failure; and, promoting acidosis, it would be unsuitable in Insulin Dependent Diabetes. Thiazide diuretics, which produce potassium loss and alkalosis, would, if in place, need to be substituted with the acetazolamide.

With these provisos, we argue that acetazolamide might offer a practical way to reduce progression of vascular calcification, a recognised risk-factor for tissue ischaemia and morbidity among the elderly population

Consequence

We suggest there exists a case for investigating its use. A population based study would be one approach, using ultrasonography [11], in subjects across an elderly age group with random assignment to treat with a sub-maximal dose (125 mg nocte or more as tolerated) of acetazolamide over a year. Alternatively, within a clinic, whether for coronary artery or peripheral vascular disease, using the same dose, a more formal open trial could be undertaken with CT, followed by a 12 months review of a chosen site. A decrease in plasma bicarbonate of ~4 mmol/L would be the objective. The subjects would almost certainly be prescribed a statin, and this would have to be standardised, particularly to achieve a targeted LDL response. Either approach could lead to interest in or rejection of the idea a subsequent formal RCT.

Conclusion

Vascular calcification is a common but undesirable process occurring with age. The final pathways in its development may be inhibited by a reduction in ambient pH. The diuretic acetazolamide which produces a mild metabolic acidosis could be trialled for possible beneficial effect.

Declaration of Competing Interest

I wrote this myself and there are no conflicts of interest.

References

[1] Bierman EL. Aging and atherosclerosis. 24th ed. New York: McGraw-Hill; 1990. p. 458–65 Chapter 45.

[2] Colin S, Chinetti-Gbaguidi G, Staels B. Macrophage phenotype in atheroma. Immunol Rev. 2014;262:153–66. https://doi.org/10.1111/imr.12218.

[3] Ceneri N, Zhao L, Young BD, et al. Rac2 modulates atherosclerotic calcification by reg- ulating macrophage IL-1beta production. Arterioscler Thromb Vasc Biol 2017;37:328–40.

[4] Lacolley P, Regnault V, Segers P, et al. Vascular smooth muscle cells and arterial stiffening: relevance in development, aging and disease. Phys Rev 2017;97:1555–617. https://doi.org/10.1152/physrev.00003.2017.

[5] Huveneers S, Daemen MJ, Hordijk PL. Between a RhOK and a hard place: the relation between vessel wall stiffness, endothelial contractility and cardiovascular disease. Circ Res 2015;116:895–908. https://doi.org/10.1152/physrev.00003.2017.

[6] Tesauro M, Mauriello A, Rovella V, et al. Arterial ageing: from endothelial dysfunction to vascular calcification. J Intern Med 2017;281:471–82. https://doi.org/10.1111/joim.12605. Epub 2017.

[7] Nicoll R, Henein MY. Arterial calcification: friend or foe? Int J Cardiol 2013;167:322–7. https://doi.org/10.1016/j.ijcard.2012.06.110. Epub 2012 Jul 17.

[8] Ewence AE, Bootman M, Roderick HL, et al. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilisation. Circ Res 2008;103:e28–34. https://doi.org/10.1161/CIRCRESAHA.108.181305. Epub 2008 Jul 31.

[9] Mauriello A, Servadei F, Zoccai GB, et al. Coronary calcification identifies the vulner- able patient rather than the vulnerable plaque. Atherosclerosis 2013;229:124–7. https://doi.org/10.1016/j.atherosclerosis.2013.03.010. Epub 2013 Mar 21.

[10] Kamenskiy A, Poulson W, Sim S, et al. Prevalence of calcification in human femoropopliteal arteries and its association with demographics, risk factors, and arterial stiffness. Arterioscler Thromb Vasc Biol 2018;38:e48–57. https://doi.org/10.1161/ATVBAHA. 117.310490. Epub 2018 Jan 25.

[11] Allison MA, Criqui MH, Wright M. Patterns and risk factors for systemic calcified atherosclerosis. Arterioscler Thromb Vasc Biol 2004;24:331–6.

[12] Evrard S, Delanaye P, Kamel S, et al. Vascular calcification: from pathophysiology to biomarkers. Clin Chim Acta 2015;438:401–14. https://doi.org/10.1016/j.cca.2014.08.034. Epub 2014 Sep 16.

[13] Leopold JA. Vascular calcification: mechanisms of vascular smooth muscle cell calcification. Trends Cardiovasc Med 2015;25:267–74. https://doi.org/10.1016/j.tcm.2014.10.021. Epub 2014 Oct 30.

[14] Puri R, Nicholls SJ, Shao M, et al. Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol 2015;65:1273–82. https://doi.org/10.1016/j.jacc.2015.01.036.

[15] Shioi A, Ikari Y. Plaque calcification during atherosclerosis progression and regression. J Atheroscler Thromb 2018;25:294–303. https://doi.org/10.5551/jat.RV17020. Epub 2017 Dec 12.

[16] MacGregor J, Robertson WG, Nordin BE. Octocalcium phosphate: the phase governing the solubility equilibrium in apatitic calculi. Br J Urol 1965;37:518–24.

[17] Robertson WG. PhD Thesis. Leeds. 1969.

[18] Orriss IR, Arnett TR, Russell RG. Pyrophosphate: a key inhibitor of mineralisation. Curr Opin Pharmacol 2016;28:57–68. https://doi.org/10.1016/j.coph.2016.03.003. Epub 2016 Apr 7.

[19] Casey P, Russell RG, Fernley HN, et al. Pyrophosphate activity of alkaline phosphatase. Helv Physiol Pharmacol Acta 1967;25. CR 174-6.

[20] Brandao-Burch A, Utting JC, Orriss IR, et al. Acidosis inhibits bone formation by osteoblasts in vitro by preventing mineralization. Calcif Tissue Int 2005;77:167–74. Epub 2005 Jul 28.

[21] Anderson HC. Vesicles associated with calcification in the matrix of epiphyseal cartilage. J Cell Biol 1969;41:59–72.

[22] Aaron JE. Osteocyte types in the developing mouse calvarium. Calc Tiss Res 1973;12:259–79.

[23] Zazzeroni L, Faggioli G, Pasquinelli G. Mechanisms of arterial calcification: the role of matrix vesicles. Eur J Vasc Endovasc Surg 2018;55:425–32. https://doi.org/10.1016/j.ejvs. 2017.12.009. Epub 2018 Jan 20.

[24] Kapustin AN, Davies JD, Reynolds JL, et al. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ Res 2011;109:e1–12. https://doi.org/10.1161/CIRCRESAHA.110.238808. Epub 2011 May 12.

[25] Ali SY, Sajdera SW, Anderson HC. Isolation and characterization of calcifying matrix vesicles from epiphyseal cartilage. Proc Natl Acad Sci USA 1970;67:1513–20.

[26] Villa-Bellosta R, Millan A, Sorribas V. Role of calcium-phosphate deposition in vascular smooth muscle cell calcification. Am J Physiol Cell Physiol 2011;300:C210–20. https://doi.org/10.1152/ajpcell.00229.2010. Epub 2010 Sep 29.

[27] Dautova Y, Kozlova D, Skepper JN, et al. Fetuin-A and albumin alter cytotoxic effects of calcium phosphate nanoparticles on human vascular smooth muscle cells. eCollection 2014 PLoS One 2014;21:9. https://doi.org/10.1371/journal.pone.0097565.

[28] Alesutan I, Feger M, Tuffaha R, et al. Augmentation of phosphate-induced osteo-/chondrogenic transformation of vascular smooth muscle cells by homoarginine. Cardiovasc Res 2016;110:408–18. https://doi.org/10.1093/cvr/cvw062. Epub 2016 Mar 21.

[29] Crouthamel MH, Lau WL, Leaf EM, et al. Sodium-dependent phosphate cotransporters and phosphate-induced calcification of vascular smooth muscle cells: redundant roles for PiT-1 and PiT-2. Arterioscler Thromb Vasc Biol 2013;33:2625–32. https://doi.org/10.1161/ATVBAHA.113.302249. Epub 2013 Aug 22.

[30] Boehme B, Schelski N, Makridakis M, et al. Role of cytosolic serine hydroxymethyl transferase 1 (SHMT1) in phosphate-induced vascular smooth muscle cell calcification. Kidney Blood Press Res 2018;43:1212–21. https://doi.org/10.1159/000492248. Epub 2018 Aug 2.

[31] Fan JL, Burgess KR, Thomas KN, et al. Effects of acetazolamide on cerebrovascular function and breathing stability at 5050 m. J Physiol 2012;590:1213–25. https://doi.org/10.1113/jphysiol.2011.219923. Epub 2012 Jan 4.

[32] Burgess KR, Lucas SJE, Burgess KME, et al. Increasing cerebral blood flow reduces the severity of central sleep apnea at high altitude. J Appl Physiol 2018;124:1341–8. https://doi.org/10.1152/japplphysiol.00799.2017. Epub 2018 Feb 1.

[33] Burgess KR, Lucas SJE, Burgess KME, et al. Increasing cerebral blood flow reduces the severity of central sleep apnea at high altitude. J Appl Physiol 2018;124:1341-8. doi: 10.1152/japplphysiol.00799.2017. Epub 2018 Feb 1.

[34] de la Horra C, Hernando N, Lambert G, et al. Molecular determinants of pH sensitivity of the type IIa Na/P(i) cotransporter. J Biol Chem 2000;275:628–37.

[35] Nowik M, Picard N, Stange G, et al. Renal phosphaturia during metabolic acidosis revisited: molecular mechanisms for decreased renal phosphate reabsorption. Pflugers Arch 2008;457:539–49. https://doi.org/10.1007/s00424-008-0530-5. Epub 2008 Jun 6.

[36] Yamaguchi T, Sugimoto T, Imai Y, et al. Successful treatment of hyperphosphatemic tumoral calcinosis with long-term acetazolamide. Bone 1995;16(4 Suppl.):247S–50S.

[37] Finer G, Price HE, Shore RM, et al. Hyperphosphatemic familial tumoral calcinosis: response to acetazolamide and postulated mechanisms. Am J Med Genet A 2014;164A:1545–9. https://doi.org/10.1002/ajmg.a.36476. Epub 2014 Mar 25.

[38] Landini-Enríquez V, Escamilla MA, Soto-Vega E, et al. Response to acetazolamide in a patient with tumoral calcinosis. Nefrologia 2015;35:503–5. https://doi.org/10.1016/j.nefro.2015.07.002. Epub 2015 Sep 19.

[39] Mendoza FJ, Lopez I, Montes de Oca A, et al. Metabolic acidosis inhibits soft tissue calcification in uremic rats. Kidney Int. 2008;73:407–14. Epub 2007 Nov 7.

[40] Lang F, Leibrock C, Pelzl L, et al. Therapeutic interference with vascular calcification—lessons from klotho-hypomorphic mice and beyond. Front Endocrinol 2018;2018(9):207–17. https://doi.org/10.3389/fendo.2018.00207.eCollection.